Sigma lines up EIA (enzyme immunoassay) products disposal for Q2
This article was originally published in Clinica
Executive Summary
Fifteen months into a three-year programme of refocusing on niche diagnostic products, NASDAQ-listed Sigma-Aldrich has said that the next stage of the strategic review could come in the second quarter, with the sale of its enzyme immunoassay (EIA) line to IVAX Diagnostics.